Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation.

× No keyword cloud information.

312 in total

1. Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase.

Authors: S Kitazume; Y Tachida; R Oka; K Shirotani; T C Saido; Y Hashimoto
Journal: Proc Natl Acad Sci U S A Date: 2001-11-06 Impact factor: 11.205

Review 2. Spotlight on BACE: the secretases as targets for treatment in Alzheimer disease.

Authors: C Dingwall
Journal: J Clin Invest Date: 2001-11 Impact factor: 14.808

3. BACE1 gene promoter single-nucleotide polymorphisms in Alzheimer's disease.

Authors: Weihui Zhou; Fang Cai; Yu Li; George S Yang; Kathleen D O'Connor; Robert A Holt; Weihong Song
Journal: J Mol Neurosci Date: 2010-05-09 Impact factor: 3.444

Review 4. Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease.

Authors: Vivian Hook; Gregory Hook; Mark Kindy
Journal: Biol Chem Date: 2010-08 Impact factor: 3.915

5. BACE2 expression increases in human neurodegenerative disease.

Authors: Christopher J Holler; Robin L Webb; Ashley L Laux; Tina L Beckett; Dana M Niedowicz; Rachel R Ahmed; Yinxing Liu; Christopher R Simmons; Amy L S Dowling; Angela Spinelli; Moshe Khurgel; Steven Estus; Elizabeth Head; Louis B Hersh; M Paul Murphy
Journal: Am J Pathol Date: 2011-11-07 Impact factor: 4.307

10. A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Abeta-induced biomarker abnormality on cultured fibroblasts.

Authors: Tapan K Khan; Thomas J Nelson; Vishal A Verma; Paul A Wender; Daniel L Alkon
Journal: Neurobiol Dis Date: 2009-02-20 Impact factor: 5.996

Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation.

1. Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase.

Review 2. Spotlight on BACE: the secretases as targets for treatment in Alzheimer disease.

3. BACE1 gene promoter single-nucleotide polymorphisms in Alzheimer's disease.

Review 4. Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease.

5. BACE2 expression increases in human neurodegenerative disease.

Review 6. Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease.

7. BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains.

8. Alzheimer disease Abeta production in the absence of S-palmitoylation-dependent targeting of BACE1 to lipid rafts.

Review 9. Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development.

10. A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Abeta-induced biomarker abnormality on cultured fibroblasts.